演題抄録

一般口演

開催概要
開催回
第56回・2018年・横浜
 

肝内胆管癌に対する術後補助化学療法におけるS-1の効果

演題番号 : O36-5

[筆頭演者]
演者)鈴木 修司:1 
[共同演者]
下田 貢:1、島崎 二郎:1、丸山 常彦:1、大城 幸雄:1、西田 清孝:1、三吉 健太:1、淺岡 純:1

1:東京医科大学茨城医療センター・消化器外科

 

Background: For recent years, intrahepatic cholangiocarcinoma was gradually increased. This retrospective study aimed to evaluate adjuvant chemotherapy using s-1 for resected intrahepatic cholangiocarcinoma.
Methodology: Nine patients who had curative resection for intrahepatic cholangiocarcinoma were classified into two groups: A, 5, surgery alone, and B, 4, surgery plus S-1 for adjuvant chemotherapy between 2008 and 2016. Outcomes, including backgrounds, disease free survival (DFS), overall survival (OS),and adverse events are reported.
Results: The mean patient age was 73.9 years (range, 61-83 years) with 2 patients of HCV, and the cohort included 5 men and 4 women. Surgical procedures included right lobectomy in 3 patients, right lobectomy in 3 patients, posterior segment resection in 2 patients, and lateral segment resection in 1 patient. There were no differences in characteristics between patients of groups A and B for age, sex, size, UICC stage, operative procedures, virus infection, infiltration, differentiation, hardness of cancer-free portion, albumin, Total bilirubin, WBC, neutrophil, lymphocyte, Hemoglobin, Platelet, CEA, CA19-9, neutrophil/lymphocyte ratio, prognostic nutritional index, and platelet/lymphocyte ratio. There was no difference between groups A and B for DFS (p=0.078) and OS (p=0.063). Grade 3/4 of adverse events were diarrhea and eruption of each one patient. Conclusions: Adjuvant chemotherapy using S-1 showed the potential tendency of contributing to prolonged DFS and OS for resected intrahepatic cholangiocarcinoma. However, a large cohort will be needed to confirm the overall efficacy in resected intrahepatic cholangiocarcinoma.

キーワード

臓器別:胆嚢・胆道

手法別:化学療法

前へ戻る